Roberto Pili is a nationally recognized expert in the areas of prostate, renal and bladder cancers. His compassionate care, innovative research and clinical studies offer patients specialty care for the best possible outcome.
- Fellowship, Clinical Research, Medical Oncology, The Johns Hopkins University Oncology Center, Baltimore, Maryland
- Residency, Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
- Post-Doctoral Fellowship, Laboratory of Biological Chemistry, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
- Residency, Internal Medicine, Catholic University School of Medicine, Rome, Italy
- Visiting Fellow, Department of Medical Microbiology and Immunology, University of South Florida, Tampa, Florida
- Doctor of Medicine, Catholic University School of Medicine, Rome, Italy, Summa Cum Laude
- American Society of Clinical Oncology
- American Association for Cancer Research
- Top Doctor, Castle Connolly Medical Ltd., 2007-2020
- Patrick C. Walsh Prostate Cancer Research Fund
- Prostate Cancer Foundation Award
- Kimmel Scholar Award
- Gaetano Fichera Fellowship - Associazione Italiana per la Ricerca sul Cancro
- Italy-Philadelphia convergence on kidney cancer research conference. “Epigenetics and kidney cancer.” UPENN-Abramson Cancer Center, Philadelphia October 10, 2019.
- Kidney Cancer Research Summit 2019 - Department of Defense. “Therapeutic targeting TFE3 in translocation renal cell carcinoma.” Philadelphia, September 12-13, 2019.
- VARI-SUC2-AACR Epigenetics Dream Team Annual Meeting: “Single cell RNA = seq to profile immune modulation upon exposure to immune checkpoint blockade and epigenetic drugs in renal cell carcinoma.” MSKCC, New York, August 13-15, 2019.
- Affronti HC, Rowsam AM, Pellerite AJ, Rosario SR, Long MD, Jacobi JJ, Bianchi-Smiraglia A, Boerlin CS, Gillard BM, Karasik E, Foster BA, Moser M, Wilton JH, Attwood K, Nikiforov MA, Azabdaftari G, Pili R, Phillips JG, Casero RA Jr., Smiraglia DJ. Phamacological polyamine catabolism upregulation with methionine salvage pathway inhibition in an effective prostate cancer therapy. Nat Commun. 2020 Jan 7;11(1):5.
- Scognamiglio G, De Chiara A, Parafioriti A, Armiraglio E, Fazioli F, Gallo M, Aversa L, Camerlingo R, Cacciatore F, Colella G, Pili R, de Nigris F. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br J Cancer. 2019 October 31.
- Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs. 2019 October 25.
- Pili R, Kauffman E, Rodriguez R (2013) Cancer of the Kidney in “Abeloff’s Clinical Oncology, 5th Edition” Niederhuber JE, Armitage JO, Doroshow JH, Kastan MD, Tepper JE. Elsevier, Philadelphia, 82:1416-1444.
- May Elbanna, Justin Budka, Paige Dausinas, Remi Adelaiye-Ogala, Nur Damayanti, Ashley Orillion, Eri Banno, Luigi Fontana, Roberto Pili (2019). Caloric restriction potentiates the therapeutic benefit of androgen deprivation therapy and alters macrophage polarization when combined with PD1 inhibition in murine models of prostate cancer. Proc AACR.